AnteoTech Ltd. advised that it has received feedback from the Therapeutic Goods Administration ("TGA") on its EuGeni Reader and SARS CoV- 2 Ag Rapid Diagnostic Test (RDT) submission. The TGA have completed a preliminary review and have requested that AnteoTech supply additional information and clarification in support of its submission. The information requested relates to the performance of AnteoTech's RDT in relation to the detection of SARS-CoV-2 variants. In addition, the TGA has requested that AnteoTech provide plans for the monitoring of the emergence of new strains of SARS-CoV-2 and performance testing of the RDT against these strains, as well as other technical and performance elements. AnteoTech is working with the TGA to provide the information as quickly as possible. The Company will provide further updates as submission progresses.